The vigilance promoting drug modafinil modulates serotonin transmission in the rat prefrontal cortex and dorsal raphe nucleus. possible relevance for its postulated antidepressant activity

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 4, 2013, Pages 478-492

  Ferraro, Luca ^a   Antonelli, Tiziana ^a   Beggiato, Sarah ^a   Tomasini, Maria Cristina ^a   Fuxe, Kjell ^b   Tanganelli, Sergio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Animal and human studies; Dorsal raphe nucleus and hippocampus; Frontal cortex; Major depression and bipolar disorder; Microdialysis; Structure activity relationship

Indexed keywords

4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; AMFEBUTAMONE; AMPHETAMINE; CATECHOLAMINE; COCAINE; FENFLURAMINE; FLUOXETINE; GALANIN; HISTAMINE; IMIPRAMINE; KETANSERIN; METHYSERGIDE; MODAFINIL; NEUROTRANSMITTER; OREXIN; PLACEBO; PRAZOSIN; PSYCHOSTIMULANT AGENT; SEROTONIN; SEROTONIN 1A RECEPTOR;

ADJUVANT THERAPY; ALERTNESS; ANTIDEPRESSANT ACTIVITY; BIPOLAR DISORDER; COGNITIVE DEFECT; DEPRESSION; DOPAMINERGIC TRANSMISSION; DORSAL RAPHE NUCLEUS; FATIGUE; HAMILTON SCALE; HUMAN; MEDIAL PREOPTIC AREA; MULTICENTER STUDY (TOPIC); NARCOLEPSY; NONHUMAN; POSTERIOR HYPOTHALAMUS; PREFRONTAL CORTEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDERED BREATHING; STRUCTURE ACTIVITY RELATION; WAKEFULNESS;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZHYDRYL COMPOUNDS; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; MENTAL DISORDERS; PREFRONTAL CORTEX; RAPHE NUCLEI; SEROTONIN; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875294447     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313040002     Document Type: Review

References (106)

1. Ballon, J.S.; Feifel, D.A. Systematic review of modafinil: Potential clinical uses and mechanisms of action. J. Clin. Psychiatry, 2006, 67(4), 554-566.
2. Minzenberg, M.J.; Carter, C.S.; Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology, 2008, 33(7), 1477-1502.
3. Sahakian, B.; Morein-Zamir, S. Professor's little helper. Nature, 2007, 450 (7173), 1157-1159.
4. Greely, H.; Sahakian, B.; Harris, J.; Kessler, R.C.; Gazzaniga, M.; Campbell, P.; Farah, M.J. Towards responsible use of cognitiveenhancing drugs by the healthy. Nature, 2008, 456(7223), 702-705.
5. Stix, G. Turbocharging the brain. Sci. Am., 2009, 301(14), 46-49, 52-55.
6. Chen, C.R.; Qu, W.M.; Qiu, M.H.; Xu, X.H.; Yao, M.H.; Urade, Y.; Huang, Z.L. Modafinil exerts a dose-dependent antiepileptic effect mediated by adrenergic alpha1 and histaminergic H1 receptors in mice. Neuropharmacology, 2007, 53(4), 534-541.
7. Kumar, R. Approved and investigational uses of modafinil: an evidence-based review. Drugs, 2008, 68(13), 1803-1839.
8. Martínez-Raga, J.; Knecht, C.; Cepeda, S. Modafinil: a useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies. Curr. Drug Abuse Rev., 2008, 1(2), 213-221.
9. Saavedra-Velez, C.; Yusim, A.; Anbarasan, D.; Lindenmayer, J.P. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J. Clin. Psychiatry, 2009, 70(1), 104-112.
10. Brown, J.N.; Howard, C.A.; Kemp, D.W. Modafinil for the treatment of multiple sclerosis-related fatigue. Ann. Pharmacother., 2010, 44(6), 1098-1103.
11. Tyne, H.L.; Taylor, J.; Baker, G.A.; Steiger, M.J. Modafinil for Parkinson's disease fatigue. J. Neurol., 2010, 257(3), 452-456.
12. Kaufman, K.R.; Menza, M.A.; Fitzsimmons, A. Modafinil monotherapy in depression. Eur. Psychiatry, 2002, 17(3), 167-169.
13. Abolfazli, R.; Hosseini, M.; Ghanizadeh, A.; Ghaleiha, A.; Tabrizi, M.; Raznahan, M.; Golalizadeh, M.; Akhondzadeh, S. Doubleblind randomized parallel-group clinical trial of efficacy of the subchronic modafinil. Psychopharmacology (Berl.), 2009, 204(4), 627-39.
14. (a) Lafon, L. U.S. Patent 4, 177, 290, 1979; (b) Lafon, L. Eur. Patent 283, 362, 1988.
15. Mu, B.; Lei, G.; He, X.; Du, X. Synthesis of central stimulant modafinil. Zhongguo Yaowu Huaxue Zazhi, 1999, 9(2), 132-134.
16. Hauck, W.; Adam, P.; Bobier, C.; Landmesser N. Use of largescale chromatography in the preparation of armodafinil. Chirality, 2008, 20(8), 896-899.
17. Robertson, P. Jr.; Hellriegel, E.T. Clinical pharmacokinetic profile of modafinil. Clin. Pharmacokinet., 2003, 42(2), 123-137.
18. Dinges, D.F.; Arora, S.; Darwish, M.; Niebler, G.E. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr. Med. Res. Opin., 2006, 22(1), 159-167.
19. Darwish, M.; Kirby, M.; D'Andrea, D.M.; Yang, R.; Hellriegel, E.T.; Robertson, P. Jr. Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. Clin. Ther., 2010, 32(12), 2074-2087.
20. Roth, T.; White, D.; Schmidt-Nowara, W.; Wesnes, K.A.; Niebler, G.; Arora, S.; Black, J. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin. Ther., 2006, 28(5), 689-706.
21. In, Y.; Tomoo, K.; Ishida, T.; Sakamoto, Y. Crystal and molecular structure of an (S)-(+)-enantiomer of modafinil, a novel wakepromoting agent. Chem Pharm Bull (Tokyo), 2004, 52(10), 1186-1189.
22. Prisinzano, T.; Podobinski, J.; Tidgewell, K.; Luo, M.; Swenson, D. Synthesis and determination of the absolute configuration of the enantiomers ofmodafinil. Tetrahedron: Asymmetry, 2004, 15, 1053-1058.
23. Cao, J.; Prisinzano, T.E.; Okunola, O.; Kopajtic, T.; Shook, M.; Katz, J.L.; Newman, A.H. Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues. ACS Med. Chem. Lett., 2010, 2(1), 48-52.
24. Zhan, H.; Tang, G.X.; Xin, Y.M.; Li, Y.F.; Li, T.; Wei, Sh.H.; Mu, B.C.; Lei, G.Q. Preliminary studies on the structure-activity and time-effect relations of the central stimulating effects of modafinil in mice. Space Med. Med. Eng. (Beijing), 2004, 17(1), 12-15.
25. Chatterjie, N.; Stables, J. P.; Wang, H.; Alexander, G. J. Antinarcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity. Neurochem. Res., 2004, 29(8), 1481-1486.
26. De Risi, C.; Ferraro, L.; Pollini, G.P.; Tanganelli, S.; Valente, F.; Veronese, A.C.; Efficient synthesis and biological evaluation of two modafinil analogues. Bioorg. Med. Chem., 2008, 16(23), 9904-9910.
27. Nasr, S.; Wendt, B.; Steiner, K. Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice. J. Affect. Disord., 2006, 95(1-3), 111-114.
28. Duteil, J.; Rambert, F.A.; Pessonnier, J.; Hermant, J.; Gombert, R.; Assous, E. Central AA1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur. J. Pharmacol., 1990, 180(1), 49-58.
29. Ferraro, L.; Antonelli, T.; O'Connor, W.T.; Tanganelli, S.; Rambert, F.A.; Fuxe, K. Modafinil: An antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol. Psychiatry, 1997, 42(12), 1181-1183.
30. Qu, W.M.; Huang, Z.L.; Xu, X.H.; Matsumoto, N.; Urade, Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J. Neurosci., 2008, 28(34), 8462-8469.
31. Volkow, N.D.; Fowler, J.S.; Logan, J.; Alexoff, D.; Zhu, W.; Telang, F.; Wang, G.J.; Jayne, M.; Hooker, J.M.; Wong, C.; Hubbard, B.; Carter, P.; Warner, D.; King, P.; Shea, C.; Xu, Y.; Muench, L.; Apelskog-Torres, K. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA, 2009, 301(11), 1148-5114.
32. Andersen, M.L.; Kessler, E.; Murnane, K.S.; McClung, J.C.; Tufik, S.; Howell, L.L. Dopamine transporter-related effects of modafinil in rhesus monkeys. Psychopharmacology (Berl.), 2010, 210(3), 439-448.
33. Paterson, N.E.; Fedolak, A.; Olivier, B.; Hanania, T.; Ghavami, A.; Caldarone, B. Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol. Biochem. Behav., 2010, 95(4), 449-456.
34. Young, J.W.; Kooistra, K.; Geyer, M.A. Dopamine Receptor Mediation of the Exploratory/Hyperactivity Effects of Modafinil. Neuropsychopharmacology, 2011, 36(7), 1385-1396.
35. Madras, B.K.; Xie, Z.; Lin, Z.; Jassen, A.; Panas, H.; Lynch, L.; Johnson, R.; Livni, E.; Spencer, T.J.; Bonab, A.A.; Miller, G.M.; Fischman, A.J. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J. Pharmacol. Exp. Ther., 2006, 319(2), 561-9.
36. Zolkowska, D.; Jain, R.; Rothman, R.B.; Partilla, J.S.; Roth, B.L.; Setola, V.; Prisinzano, T.E.; Baumann, M.H. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J. Pharmacol. Exp. Ther., 2009, 329(2), 738-746.
37. Schmitt, K.C.; Reith, M.E. The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS One, 2011, 6(10), e25790.
38. Fuxe, K.; Dahlström, A.B.; Jonsson, G.; Marcellino, D.; Guescini, M.; Dam, M.; Manger, P.; Agnati L. The discovery of central monoamine neurons gave volume transmission to the wired brain. Prog. Neurobiol., 2010, 90(2):82-100.
39. Minzenberg, M.J.; Watrous, A.J.; Yoon, J.H.; Ursu, S.; Carter, C.S. Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI. Science, 2008, 322(5908), 1700-1702.
40. Minzenberg, M.J.; Yoon, J.H.; Carter, C.S. Modafinil modulation of the default mode network. Psychopharmacology (Berl.), 2011, 215(1), 23-31.
41. Shelton, R.C.; Reddy, R. Adjunctive use of modafinil in bipolar patients: just another stimulant or not? Curr. Psychiatry Rep., 2008, 10(6), 520-524.
42. McClellan, K.J.; Spencer, C.M. Modafinil: a review of its pharmacology and clinical efficacy in the management of narcolepsy. CNS Drugs, 1998, 9(4), 311-324.
43. Ferraro, L.; Antonelli, T.; O'Connor, W.T.; Tanganelli, S.; Rambert, F.A.; Fuxe, K. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport, 1997, 8(13), 2883-2887.
44. Ferraro, L.; Antonelli, T.; Tanganelli, S.; O'Connor, W.T.; Perez de la Mora, M.; Mendez-Franco, J.; Rambert, F.A.; Fuxe, K. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAa receptor blockade. Neuropsychopharmacology, 1999, 20(4), 346-356.
45. Tanganelli, S.; Fuxe, K.; Ferraro, L.; Janson, A.M.; Bianchi, C. Inhibitory effects of the psychoactive drug modafinil on gammaaminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxytryptamine mechanisms. Naunyn-Schmiedebergs Arch. Pharmacol., 1992, 345(4), 461-465.
46. Tanganelli, S.; Ferraro, L.; Bianchi, C.; Fuxe, K. 6-Hydroxydopamine treatment counteracts the reduction of cortical GABA release produced by the vigilance promoting drug modafinil in the awake freely moving guinea-pig. Neurosci. Lett., 1994, 171(1-2), 201-204.
47. Tanganelli, S.; Perez de la Mora, M.; Ferraro, L.; Méndez-Franco, J.; Beani, L.; Rambert, F.A.; Fuxe, K. Modafinil and cortical gammaaminobutyric acid outflow: modulation by 5-hydroxytryptamine neurotoxins. Eur. J. Pharmacol., 1995, 273(1-2), 63-71.
48. Ferraro, L.; Antonelli, T.; O'Connor, W.T.; Tanganelli, S.; Rambert, F.A.; Fuxe, K. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci. Lett., 1998, 253(2), 135-138.
49. Ishizuka, T.; Sakamoto, Y.; Sakurai, T.; Yamatodani, A. Modafi nil increases histamine release in the anterior hypothalamus of rats. Neurosci. Lett., 2003, 339(2), 143-146.
50. Ishizuka, T.; Murakami, M.; Yamatodani, A. Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats. Eur. J. Pharmacol., 2008, 578(2-3), 209-215.
51. Ferraro, L.; Fuxe, K.; Tanganelli, S.; Fernandez, M.; Rambert, F.A.; Antonelli, T. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology, 2000, 39(11), 1974-1983.
52. Ferraro, L.; Fuxe, K.; Tanganelli, S.; Tomasini, M.C.; Rambert, F.A.; Antonelli T. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J. Neurosci. Res., 2002, 168(1), 107-112.
53. Ferraro, L.; Fuxe, K.; Agnati, L.; Tanganelli, S.; Tomasini, M.C.; Antonelli, T. Modafinil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fluoxetine and imipramine: a dual probe microdialysis study in awake rat. Synapse, 2005, 55(4), 230-241.
54. Ishizuka, T.; Murotani, T.; Yamatodani, A. Modanifil activates the histaminergic system through the orexinergic neurons. Neurosci. Lett., 2010, 483(3),193-196.
55. Scammell, T.E.; Estabrooke, I.V.; McCarthy, M.T.; Chemelli, R.M.; Yanagisawa, M.; Miller, M.S.; Saper, C.B. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J. Neurosci., 2000, 20(22), 8620-8628.
56. Ferraro, L.; Tanganelli, S.; O'Connor, W.T.; Antonelli, T.; Rambert, F.; Fuxe, K. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur. J. Pharmacol., 1996, 306(1-3), 33-39.
57. Ferraro, L.; Tanganelli, S.; O'Connor W.T.; Antonelli, T.; Rambert, F.A.; Fuxe, K. The vigilance promoting drug modafinil decreases GABA release in the medial preotic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci. Letts., 1996, 220(1), 5-8.
58. Antonelli, T.; Ferraro, L.; Hillion, J.; Tomasini, M.C.; Rambert, F.A.; Fuxe, K. Modafinil prevents glutamate cytotoxicity in cultured cortical neurons. Neuroreport, 1998, 9(18), 4209-4213.
59. Menza, M.A.; Kaufman, K.R.; Castellanos, A. Modafinil augmentation of antidepressant treatment in depression. J. Clin. Psychiatry, 2000, 61(5), 378-381.
60. DeBattista, C.; Doghramji, K.; Menza, M.A.; Rosenthal, M.H.; Fieve, R.R. Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary doubleblind, placebo-controlled study. J. Clin. Psychiatry, 2003, 64(9), 1057-64.
61. Fava, M.; Thase, M.E.; DeBattista, C. A multicenter, placebocontrolled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J. Clin. Psychiatry, 2005, 66(1), 85-93.
62. Fava. M.; Thase, M.E.; DeBattista, C.; Doghramji, K.; Arora, S.; Hughes, R.J. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann. Clin. Psychiatry, 2007, 19(3), 153-159.
63. Dunlop, B.W.; Crits-Christoph, P.; Evans, D.L.; Hirschowitz, J.; Solvason, H.B.; Rickels, K.; Garlow, S.J.; Gallop, R.J.; Ninan, P.T. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebocontrolled study. J. Clin. Psychopharmacol., 2007, 27(6), 614-619.
64. Ninan, P.T.; Hassman, H.A.; Glass, S.J.; McManus, F.C. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue J. Clin. Psychiatry, 2004, 65(3), 414-20.
65. Schwartz, T.L.; Azhar, N.; Cole, K.; Hopkins, G.; Nihalani, N.; Simionescu, M.; Husain, J.; Jones, N. An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. J. Clin. Psychiatry, 2004, 65(9), 1223-1227.
66. Price, C.S.; Taylor, F.B. A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy. Depress. Anxiety, 2005, 21(4), 149-153.
67. Rasmussen, N.A.; Schrøder, P.; Olsen, L.R.; Brødsgaard, M.; Undén, M.; Bech, P. Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on selfreported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92). Nord J. Psychiatry, 2005, 59(3), 173-178.
68. Konuk, N.; Atasoy, N.; Atik, L.; Akay, O. Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors. Adv. Ther. 2006, 23(4),646-654.
69. Thase, M.E.; Fava, M.; DeBattista, C.; Arora, S.; Hughes, R.J. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr., 2006, 11(2), 93-102.
70. Taneja, I.; Haman, K.; Shelton, R.C.; Robertson, D. A randomized, double-blind, crossover trial of modafinil on mood. J. Clin. Psychopharmacol., 2007, 27(1), 76-79.
71. Belmaker, R.H. Modafinil add-on in the treatment of bipolar depression. Am. J. Psychiatry, 2007, 164(8), 1143-1145.
72. Black, W.; Hoey, P.; Mayze, T. Modafinil use in patients with a primary psychiatric illness. Aust. N.Z. J. Psychiatry, 2010, 44(6),583-584.
73. Fernandes, P.P.; Petty, F. Modafinil for remitted bipolar depression with hypersomnia. Ann. Pharmacother., 2003, 37(12), 1807-1809.
74. Frye, M.A.; Grunze, H.; Suppes, T.; McElroy, S.L.; Keck, P.E. Jr.; Walden, J.; Leverich, G.S.; Altshuler, L.L.; Nakelsky, S.; Hwang, S.; Mintz, J.; Post, R.M. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am. J. Psychiatry, 2007, 164(8), 1242-1249.
75. Wolf, J.; Fiedler, U.; Anghelescu, I.; Schwertfeger, N. Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil. J. Clin. Psychiatry, 2006, 67(11), 1817.
76. Calabrese, J.R.; Ketter, T.A.; Youakim, J.M.; Tiller, J.M.; Yang, R.; Frye, M.A. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J. Clin. Psychiatry, 2010, 71(10), 1363-1370.
77. Regenthal, R.; Koch, H.; Köhler, C.; Preiss, R.; Krügel, U. Depression-like deficits in rats improved by subchronic modafinil. Psychopharmacology (Berl.), 2009; 204(4), 627-639.
78. DeBattista, C.; Lembke, A.; Solvason, H.B.; Ghebremichael, R.; Poirier, J. A prospective trial of modafinil as an adjunctive treatment of major depression. J. Clin. Psychopharmacol., 2004, 24(1), 87-90.
79. Moreira, K.M.; Ferreira, T.L.; Hipolide, D.C.; Fornari, R.V.; Tufik, S.; Oliveira, M.G. Modafinil prevents inhibitory avoidance memory deficit induced by sleep deprivation in rats. Sleep, 2010, 33(7), 990-993.
80. Piérard, C.; Liscia, P.; Chauveau, F.; Coutan, M.; Corio, M.; Krazem, A.; Beracochea, D. Differential effects of total sleep deprivation on contextual and spatial memory: modulatory effects of modafinil. Pharmacol. Biochem. Behav., 2011, 97(3), 399-405.
81. Carvalho, A.F.; Cavalcante, J.L.; Castelo, M.S.; Lima, M.C. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther 2007; 32: 415-28.
82. Ng, B. Psychostimulants and treatment resistant depression. Acta Psychiatr Scand 2009; 120: 502-3.
83. Nicolaidis, S.; De Saint Hilaire, Z. Nonamphetamine awakening agent modafinil induces feeding changes in the rat. Brain Res. Bull., 1993; 32(2), 87-90.
84. de Saint Hilaire, Z.; Orosco, M.; Rouch, C.; Blanc, G.; Nicolaidis, S. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport, 2001, 12(16), 3533-7.
85. Gallopin, T.; Luppi, P.H.; Rambert, F.A.; Frydman, A.; Fort, P. Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep, 2004, 27(1), 19-25.
86. Mignot, E.; Nishino, S.; Guilleminault, C.; Dement, W.C. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994; 17: 436-7.
87. Gobbi, M.; Frittoli, E.; Mennini, T.; Garattini, S. Releasing activities of d-fenfluramine and fluoxetine on rat hippocampal synaptosomes preloaded with [3H]serotonin. Naunyn-Schmiedeberg's Arch. Pharmacol., 1992, 345(1), 1-6.
88. Sharp, T.; Bramwell, S.R.; Grahame-Smith, D.G. 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br. J. Pharmacol., 1989, 96(1), 283-290.
89. Ferraro, L.; Tanganelli, S.; Fuxe, K.; Bebe, B.W.; Tomasini, M.C.; Rambert, F.A.; Antonelli, T. Modafinil does not affect serotonin efflux from rat frontal cortex synaptosomes: comparison with known serotonergic drugs. Brain Res., 2001, 894(2), 307-310.
90. Fuxe, K.; Rambert, F.A.; Ferraro, L.; O'Connor, W.T.; Laurent, P.H.; Agnati, L.F.; Tanganelli, S. Preclinical studies with modafinil. Evidence for vigilance enhancement and neuroprotection. Drugs Today, 1996, 32(4), 313-326.
91. Savitz, J.; Lucki, I.; Drevets, W.C. 5-HT(1A) receptor function in major depressive disorder. Prog. Neurobiol., 2009, 88(1), 17-31.
92. Sherin, J.E.; Elmquist, J.K.; Torrealba, F.; Saper, C.B. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J. Neurosci., 1998, 18(12), 4705-4721.
93. Ogren, S.O.; Kuteeva, E.; Hökfelt, T.; Kehr, J. Galanin receptor antagonists: a potential novel pharmacological treatment for mood disorders. CNS Drugs, 2006, 20(8), 633-654.
94. Lu, X.; Sharkey, L.; Bartfai, T. The brain galanin receptors: targets for novel antidepressant drugs. CNS Neurol. Disord. Drug Targets, 2007, 6(3), 183-192.
95. Fuxe, K.; Hedlund, P.; von Euler, G.; Lundgren, K.; Martire, M.; Ögren, S.O.; Eneroth, P.; Agnati, L.F. In Galanin. A new Multifunctional peptide in the neuroendocrine system; Hökfelt, T.;Bartfai, T.; Jacobowitz, D.; Ottoson, D., Eds.; Macmillan Press, London, 1991; Wenner-Gren Int Series Vol. 58, pp. 221-235.
96. Fuxe, K.; von Euler, G.; Agnati, L.F.; Ogren, S.O. Galanin selectively modulates 5-hydroxytryptamine 1A receptors in the rat ventral limbic cortex. Neurosci. Letts., 1988, 85, 163-167.
97. Razani, H.; Diaz-Cabiale, Z.; Fuxe, K.; Ogren, S.O. Intraventricular galanin produces a time-dependent modulation of 5-HT1A receptors in the dorsal raphe of the rat. Neuroreport, 2000, 11(18), 3943-3948.
98. Hedlund, P.B.; Fuxe, K. Galanin and 5-HT1A receptor interactions as an integrative mechanism in 5-HT neurotransmission in the brain. Ann. N.Y. Acad. Sci., 1996, 780(), 193-212.
99. Borroto-Escuela, D.O.; Narvaez, M.; Marcellino, D.; Parrado, C.; Narvaez, J.A.; Tarakanov, A.O.; Agnati, L.F.; Díaz-Cabiale, Z.; Fuxe, K. Galanin receptor-1 modulates 5-hydroxtryptamine-1A signaling via heterodimerization. Biochem. Biophys. Res. Commun., 2010, 393(4), 767-72.
100. Celada, P.; Puig, M.V.; Casanovas, J.M.; Guillazo, G.; Artigas, F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: Involvement of serotonin-1A, GABA(A), and glutamate receptors. J. Neurosci., 2001, 21(24), 9917-9929.
101. Piérard, C.; Liscia, P.; Valleau, M.; Drouet, I.; Chauveau, F.; Huart, B.; Bonneau, D.; Jouanin, J.C.; Beaumont, M.; Béracochéa, D. Modafinil-induced modulation of working memory and plasma corticosterone in chronically-stressed mice. Pharmacol. Biochem. Behav., 2006, 83(1), 1-8.
102. Béracochéa, D.; Liscia, P.; Tronche, C.; Chauveau, F.; Jouanin, J.C.; Piérard, C. Stress modulation of the memory retrogradeenhancing effects of the awakening drug modafinil in mice. Psychopharmacology (Berl.), 2008, 196(1), 1-13.
103. Gourley, S.L.; Wu, F.J.; Kiraly, D.D.; Ploski, J.E.; Kedves, A.T.; Duman, R.S.; Taylor, J.R. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol Psychiatry, 2008, 63(4), 353-359.
104. Murray, F.; Smith, D.W.; Hutson, P.H. Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. Eur. J. Pharmacol., 2008, 583(1), 115-127.
105. Herman, J.P.; Ostrander, M.M.; Mueller, N.K.; Figueiredo, H. Limbic system mechanisms of stress regulation: hypothalamopituitary-adrenocortical axis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2005, 29(8), 1201-1213.
106. Videbech, P. Modafinil in the treatment of depression-a systematic review. Ugeskr Laeger, 2012, 174(6), 348-351.